{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:09:44Z","timestamp":1780805384801,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jim.2024.113717","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T04:51:30Z","timestamp":1719895890000},"page":"113717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Belimumab concentration measurements using a homologous anti-idiotype immunoassay"],"prefix":"10.1016","volume":"532","author":[{"given":"Floris C.","family":"Loeff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Walhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"J\u00f6nsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A.","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorn","family":"Jeremiasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit S.","family":"Blomjous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit Jan","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene E.M.","family":"Bultink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jim.2024.113717_bb0005","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jim.2024.113717_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/rheumatology\/kead253","article-title":"Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials","volume":"63","author":"Gomez","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jim.2024.113717_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1814661","article-title":"Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics","volume":"12","author":"Grosserichter-Wagener","year":"2020","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.jim.2024.113717_bb0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jim.2024.113717_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115730","article-title":"Determination of plasma concentration of Belimumab by LC-MS\/MS: method development, validation, and clinical application","volume":"236","author":"Marin","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10","key":"10.1016\/j.jim.2024.113717_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103463","article-title":"Autoantibody and cytokine profiles during treatment with Belimumab in patients with systemic lupus erythematosus","volume":"21","author":"Parodis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.jim.2024.113717_bb0035","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","article-title":"De novo lupus nephritis during treatment with belimumab","volume":"60","author":"Parodis","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jim.2024.113717_bb0040","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ekir.2023.06.021","article-title":"Effect of Belimumab on preventing de novo renal lupus flares","volume":"8","author":"Parodis","year":"2023","journal-title":"Kidney Int. Rep."},{"issue":"2","key":"10.1016\/j.jim.2024.113717_bb0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.jim.2024.113717_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086184","article-title":"A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood","volume":"9","author":"Seeber","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jim.2024.113717_bb0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/03009742.2014.887769","article-title":"Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity","volume":"43","author":"Sjowall","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"6","key":"10.1016\/j.jim.2024.113717_bb0060","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.semarthrit.2016.09.006","article-title":"New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab","volume":"46","author":"Staveri","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jim.2024.113717_bb0065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity","volume":"7","author":"van Schie","year":"2015","journal-title":"mAbs"},{"issue":"50","key":"10.1016\/j.jim.2024.113717_bb0070","doi-asserted-by":"crossref","first-page":"34482","DOI":"10.1074\/jbc.M114.615500","article-title":"Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies","volume":"289","author":"van Schouwenburg","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jim.2024.113717_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymeth.2013.07.018","article-title":"A simple, robust and highly efficient transient expression system for producing antibodies","volume":"65","author":"Vink","year":"2014","journal-title":"Methods"},{"issue":"12","key":"10.1016\/j.jim.2024.113717_bb0080","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1345\/aph.1P360","article-title":"Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus","volume":"44","author":"Wiglesworth","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jim.2024.113717_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2023.110706","article-title":"Rapid and simple quantification of belimumab in human plasma using ultra-high performance liquid chromatography with tandem mass spectrometry","volume":"124","author":"Yoshijima","year":"2024","journal-title":"Clin. Biochem."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:57:29Z","timestamp":1739840249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175924001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"alternative-id":["S0022175924001029"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2024.113717","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belimumab concentration measurements using a homologous anti-idiotype immunoassay","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2024.113717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113717"}}